Ciluprevir
Ciluprevir was a drug used experimentally in the treatment of hepatitis C.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Ciluprevir was a drug used experimentally in the treatment of hepatitis C. It is manufactured by Boehringer Ingelheim and developed under the research code of BILN 2061. It was the first-in-class NS3/4A protease inhibitor to enter clinical development and tested in human.
Ciluprevir is a potent competitive reversible inhibitor of NS3/4A protease from HCV genotype 1a (K i = 0.3 nM) and 1b (K i = 0.66 nM). It shows good selectivity for NS3 protease against representative serine and cysteine proteases, human leukocyte elastase and cathepsin B (IC 50 > 30 μM). Its development was halted in phase Ib clinical trials because of toxicity in animals.
However, ciluprevir scaffold was exploited to design new macrocyclic inhibitors such as simeprevir (TMC-435) and danoprevir.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1341981054 under CC BY-SA 4.0; modifications have been made.